<DOC>
	<DOC>NCT02753543</DOC>
	<brief_summary>This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of chemotherapy in interim evaluation.</brief_summary>
	<brief_title>Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<criteria>Pathologically verified peripheral Tcell lymphoma, partial response or stable disease after 3 cycles of CEOP (cyclophosphamide, epirubicin or doxorubicin, vincristine and prednisone) or CEOP(cyclophosphamide,vincristin,epirubicin and prednisone)/IVE (ifosfamide, epirubicin, etoposide)/GDP(Gemcitabine, Cisplatinum, Dexamethasone) Age ≧16 years, ≦75 years ECOG (Eastern Cooperative Oncology Group) =0,1,2 No previous history of malignancy Radiologically measurable disease Life expectancy&gt;6 months Informed consented Active infectious disease requiring general antibiotics, antifungal or antivirus therapy Lab at enrollment(unless caused by lymphoma) Neutrophile&lt;1.5*10^9/L Platelet&lt;75*10^9/L Hemoglobulin&lt;90g/L ALT(alanine aminotransferase) or AST (aspartate aminotransferase ) &gt;2*ULN,AKP(alkaline phosphatase) or bilirubin &gt;1.5*ULN (upper limit of normal ) Creatinine&gt;1.5*ULN Other uncontrollable medical condition that may that may interfere the participation of the study Not able to comply to the protocol for mental or other unknown reasons Pregnant or lactation HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>